ABIVAX Société Anonyme announced the following: Appointment of Michael Ferguson as Chief Commercial Officer: In April 2023, Abivax announced the appointment of Michael Ferguson as new Chief Commercial Officer, effective immediately. He has a strong track record in the biopharmaceutical industry, having held senior positions for commercialization and marketing of drugs in the field of Gastroenterology and specifically in IBD. As CCO of Abivax, Michael Ferguson will be leading the market development of obefazimod in IBD.

Appointment of Pierre Courteille Ferguson as Chief Business Officer: In parallel to the appointment of Michael Ferguson as new CCO, Pierre Courteille was appointed Chief Business Officer of Abivax in April 2023. Abivax Board of Directors recomposition: As from May 5, 2023, Mr. Marc de Garidel will join the Board of Directors and serve as Chairman on an interim basis. Dr. Philippe Pouletty will become Truffle Capital's permanent representative on the Board in replacement of Mr. Christian Pierret.

Ms. Corinna zur Bonsen-Thomas will cease to act as Chairman but will retain her functions as director.